Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
Public ClinicalTrials.gov record NCT04157335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus placebo in patients with severe nasal polyposis.
Study identification
- NCT ID
- NCT04157335
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 295 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 25, 2019 (Actual)
- Primary completion
- Aug 6, 2024 (Actual)
- Completion
- Apr 7, 2025 (Actual)
- Last update posted
- Feb 19, 2026
2019 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Huntington Beach | California | 92647 | — |
| Research Site | Grand Junction | Colorado | 81501 | — |
| Research Site | Gainesville | Florida | 32605 | — |
| Research Site | Louisville | Kentucky | 40220 | — |
| Research Site | White Marsh | Maryland | 21162 | — |
| Research Site | The Bronx | New York | 10461 | — |
| Research Site | White Plains | New York | 10605 | — |
| Research Site | Tulsa | Oklahoma | 74136 | — |
| Research Site | Bethlehem | Pennsylvania | 18017 | — |
| Research Site | Fort Worth | Texas | 76109 | — |
| Research Site | McKinney | Texas | 75070 | — |
| Research Site | St. George | Utah | 84790 | — |
| Research Site | Richmond | Virginia | 23235 | — |
| Research Site | Bellingham | Washington | 98225 | — |
| Research Site | Milwaukee | Wisconsin | 53228 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04157335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04157335 live on ClinicalTrials.gov.